In the last 4 years, 6 phase 3 trials including a total of 27 023 patients with venous
thromboembolism (VTE) compared a direct oral anticoagulant (DOAC) with vitamin K antagonists (…

Deep vein thrombosis and pulmonary embolism, collectively referred to as venous
thromboembolism, constitute a major global burden of disease. The diagnostic work-up of suspected …

… the Khorana score was not reported (n=31), VTE incidence was not reported (n=6), the study
… (n=6), the cohort was a duplicate report (n=5), or the study had a case-control design (n=2). …

… van Es reports fees paid to his institution, outside the present work, from Bayer, LEO
Pharma… Saskia Middeldorp, Michiel Coppens, and Nick van Es drafted the first version of the …

Background Low-molecular-weight heparin is the standard treatment for cancer-associated
venous thromboembolism. The role of treatment with direct oral anticoagulant agents is …

A potential link between mortality, d-dimer values, and a prothrombotic syndrome has been
reported in patients with coronavirus disease 2019 (COVID-19) infection. The National …

The incidence of venous thromboembolism (VTE) in cancer patients may have changed in
the past decade, possibly due to novel cancer therapies, improved survival, and high-…

… they had a primary brain tumour (n=240), unavailable D-dimer values (n=16), or lymphoma
that could not be staged by Ann Arbor (n=5), because they were lost to follow-up (n=39), or …

Direct oral anticoagulants (DOACs) are an emerging treatment option for patients with cancer
and acute venous thromboembolism (VTE), but studies have reported inconsistent results. …

In ambulatory patients with solid cancer, routine thromboprophylaxis to prevent venous
thromboembolism is not recommended. Several risk prediction scores to identify cancer patients …